CUSIP 90240B106 · who reports it, how much, and how much it matters to them
23 of the 720 hedge fund managers we track reported shares of Tyra Biosciences, Inc. (Nasdaq: TYRA) on Form 13F for 30 June 2026. Between them they reported USD 500m. The largest position belongs to Ra Capital Management, at USD 390m. The manager with the most riding on it is Sio Capital Management, where it is 3.7% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Ra Capital Management1 fund on PPLI.com | USD 390m | 3.4% |
| 2 | Sio Capital Management4 funds on PPLI.com | USD 22m | 3.7% |
| 3 | Marshall Wace LLP84 funds on PPLI.com | USD 19m | 0.0% |
| 4 | Two Sigma Investments35 funds on PPLI.com | USD 14m | 0.0% |
| 5 | Walleye Capital8 funds on PPLI.com | USD 11m | 0.0% |
| 6 | Citadel Advisors32 funds on PPLI.com | USD 8.9m | 0.0% |
| 7 | HighVista Strategies27 funds on PPLI.com | USD 5.9m | 1.3% |
| 8 | Millennium Management6 funds on PPLI.com | USD 5.7m | 0.0% |
| 9 | Boothbay Fund Management2 funds on PPLI.com | USD 5.5m | 0.1% |
| 10 | Adage Capital Management1 fund on PPLI.com | USD 5.2m | 0.0% |
| 11 | Orbimed Advisors1 fund on PPLI.com | USD 3.3m | 0.1% |
| 12 | Squarepoint Ops7 funds on PPLI.com | USD 2m | 0.0% |
| 13 | Exoduspoint Capital Management7 funds on PPLI.com | USD 1.3m | 0.0% |
| 14 | Verdad Advisers6 funds on PPLI.com | USD 1.1m | 1.1% |
| 15 | Sofinnova Investments1 fund on PPLI.com | USD 1m | 0.1% |
| 16 | Engineers Gate Manager1 fund on PPLI.com | USD 1m | 0.0% |
| 17 | LMR Partners2 funds on PPLI.com | USD 676,000 | 0.0% |
| 18 | D. E. Shaw & Co.15 funds on PPLI.com | USD 645,000 | 0.0% |
| 19 | Baker Bros. Advisors2 funds on PPLI.com | USD 339,000 | 0.0% |
| 20 | Cinctive Capital Management5 funds on PPLI.com | USD 325,000 | 0.0% |
| 21 | Capstone Investment Advisors25 funds on PPLI.com | USD 321,000 | 0.0% |
| 22 | Jain Global1 fund on PPLI.com | USD 275,000 | 0.0% |
| 23 | The Quarry1 fund on PPLI.com | USD 383 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Sio Capital Management | USD 22m | 3.7% |
| 2 | Ra Capital Management | USD 390m | 3.4% |
| 3 | HighVista Strategies | USD 5.9m | 1.3% |
| 4 | Verdad Advisers | USD 1.1m | 1.1% |
| 5 | Boothbay Fund Management | USD 5.5m | 0.1% |
| 6 | Orbimed Advisors | USD 3.3m | 0.1% |
| 7 | Sofinnova Investments | USD 1m | 0.1% |
| 8 | Walleye Capital | USD 11m | 0.0% |
| 9 | Marshall Wace LLP | USD 19m | 0.0% |
| 10 | Engineers Gate Manager | USD 1m | 0.0% |
Tyra Biosciences, Inc. trades under the symbol TYRA on the Nasdaq. Its CUSIP, the code used on Form 13F, is 90240B106.
23 of the 720 hedge fund managers PPLI.com tracks reported Tyra Biosciences, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Ra Capital Management (USD 390m), Sio Capital Management (USD 22m), Marshall Wace LLP (USD 19m), Two Sigma Investments (USD 14m) and Walleye Capital (USD 11m).
23 managers in our coverage reported it, and between them they run 274 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Sio Capital Management, where the position was 3.7% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Tyra Biosciences, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.